東山精密(002384.SZ):擬與江蘇博融等機構共設合夥企業 預計總規模為33億元
格隆匯9月2日丨東山精密(002384.SZ)公佈,公司擬與江蘇博融股權投資合夥企業(有限合夥)(“江蘇博融”)等機構共同設立江蘇博華股權投資合夥企業(有限合夥)(“江蘇博華”或“合夥企業”)。合夥企業預計總規模為33億元,合夥企業的出資額、合夥人名冊及出資比例等信息以工商登記為準。
其中,東山精密作為有限合夥人擬認繳出資5億元,江蘇博融作為普通合夥人擬認繳出資2000萬元,其他有限合夥人合計認繳出資約27.8億元。
投資方向:重點投資以下行業領域內的標的公司或主要投資於以下行業領域內的資產組合:科技、消費、醫療領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.